BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:galvokimig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of galvokimig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07277660-1380@assetmemo.bio
DTSTAMP:20261121T005859Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:galvokimig: Phase 2 readout est. (NCT07277660)
DESCRIPTION:galvokimig\, phase 2\, Atopic Dermatitis.\nStudy: A Dose-rangin
 g Study to Evaluate the Efficacy\, Safety\, Pharmacokinetics\, and Pharmac
 odynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
 \nEstimated primary completion: 17 May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/galvokimig#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07277660
URL:https://assetmemo.bio/drug/galvokimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720375-1380@assetmemo.bio
DTSTAMP:20261121T005859Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:galvokimig: Phase 2 readout est. (NCT07720375)
DESCRIPTION:galvokimig\, phase 2.\nStudy: A Study of 24 to 52 Weeks Treatme
 nt to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Partic
 ipants With Non-Cystic Fibrosis Bronchiectasis\nEstimated primary completi
 on: 28 February 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /galvokimig#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07720375
URL:https://assetmemo.bio/drug/galvokimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07725939-1380@assetmemo.bio
DTSTAMP:20261121T005859Z
DTSTART;VALUE=DATE:20290629
DTEND;VALUE=DATE:20290630
SUMMARY:galvokimig: Phase 2 readout est. (NCT07725939)
DESCRIPTION:galvokimig\, phase 2.\nStudy: A Study of 24 to 52 Weeks Treatme
 nt to Evaluate The Efficacy And Safety of Galvokimig in Study Participants
  With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With
  Chronic Bronchitis\nEstimated primary completion: 29 June 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/galvokimig#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07725939
URL:https://assetmemo.bio/drug/galvokimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
